SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Arkema S.A. (ARKAF) trades at a trailing P/E of 78.7, forward P/E of 13.7. Trailing earnings yield is 1.27%, forward earnings yield 7.32%. PEG 0.03 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (15/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 78.7).
- Forward P/E 13.7 (down from trailing 78.7) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.03 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 1.27% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 7.32% as earnings recover.
Overall SharesGrow Score: 43/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
15/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ARKAF
Valuation Multiples
P/E (TTM)78.7
Forward P/E13.7
PEG Ratio0.03
Forward PEG0.03
P/B Ratio0.00
P/S Ratio0.55
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.83
Forward EPS (Est.)$4.78
Book Value / Share$0.00
Revenue / Share$119.32
FCF / Share$0.00
Yields & Fair Value
Earnings Yield1.27%
Forward Earnings Yield7.32%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$5.66 |
$7.54B |
$427M |
5.7% |
| 2017 |
$7.15 |
$8.33B |
$576M |
6.9% |
| 2018 |
$9.26 |
$8.82B |
$707M |
8% |
| 2019 |
$6.41 |
$8.74B |
$543M |
6.2% |
| 2020 |
$3.96 |
$7.88B |
$332M |
4.2% |
| 2021 |
$17.04 |
$9.52B |
$1.31B |
13.8% |
| 2022 |
$12.75 |
$11.55B |
$965M |
8.4% |
| 2023 |
$5.36 |
$9.51B |
$418M |
4.4% |
| 2024 |
$4.29 |
$9.54B |
$354M |
3.7% |
| 2025 |
$0.83 |
$9.06B |
$62.98M |
0.7% |
